Bristol-Myers Squibb Company (BMY) Holdings Increased by Strs Ohio
Strs Ohio raised its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 8.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,725,265 shares of the biopharmaceutical company’s stock after purchasing an additional 128,111 shares during the period. Strs Ohio owned approximately 0.10% of Bristol-Myers Squibb worth $96,131,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of BMY. Ledyard National Bank boosted its stake in Bristol-Myers Squibb by 25.5% during the 1st quarter. Ledyard National Bank now owns 27,248 shares of the biopharmaceutical company’s stock valued at $1,482,000 after purchasing an additional 5,533 shares during the last quarter. Bollard Group LLC boosted its stake in Bristol-Myers Squibb by 7.8% during the 1st quarter. Bollard Group LLC now owns 186,473 shares of the biopharmaceutical company’s stock valued at $10,140,000 after purchasing an additional 13,425 shares during the last quarter. Beech Hill Advisors Inc. boosted its stake in Bristol-Myers Squibb by 59.6% during the 1st quarter. Beech Hill Advisors Inc. now owns 15,000 shares of the biopharmaceutical company’s stock valued at $816,000 after purchasing an additional 5,600 shares during the last quarter. Sabal Trust CO boosted its stake in Bristol-Myers Squibb by 78.1% during the 1st quarter. Sabal Trust CO now owns 8,665 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 3,800 shares during the last quarter. Finally, Sanders Morris Harris Inc. purchased a new stake in Bristol-Myers Squibb during the 1st quarter valued at $360,000. Institutional investors and hedge funds own 68.88% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at 63.33 on Friday. The stock has a market cap of $103.86 billion, a price-to-earnings ratio of 23.13 and a beta of 1.18. The firm has a 50-day moving average price of $58.94 and a 200-day moving average price of $56.02. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $63.74.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.69 earnings per share. On average, equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a $0.39 dividend. The ex-dividend date is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.46%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.
Several analysts have commented on BMY shares. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 target price on the stock in a research note on Monday, June 5th. BMO Capital Markets reissued a “sell” rating and set a $49.00 price target on shares of Bristol-Myers Squibb in a report on Monday, September 4th. Jefferies Group LLC reissued a “buy” rating and set a $64.00 price target on shares of Bristol-Myers Squibb in a report on Monday, June 5th. BidaskClub raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, Deutsche Bank AG set a $55.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, July 17th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $62.20.
In other news, Director Theodore R. Samuels II acquired 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was acquired at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.